Rise in demand for effective and affordable techniques to assess the safety of drugs.

WILMINGTON, DELAWARE, UNITED STATES, October 27, 2023 /EINPresswire.com/ — Multiparametric In-vitro Cardiotoxicity Testing Market is expected to experience significant growth over the next decade. In 2021, the industry was valued at USD 44.5 million and is anticipated to expand rapidly at a compound annual growth rate of 13.9% from 2022 to 2031. Driven by rising drug development and safety testing requirements, the market size is forecasted to reach over USD 166.5 million by 2031.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗣𝗿𝗲𝗺𝗶𝘂𝗺 𝗥𝗲𝗽𝗼𝗿𝘁 @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85319

Multiparametric in-vitro cardiotoxicity testing allows researchers to evaluate potential cardiac side effects of new drug candidates earlier in the development process before clinical trials. This helps pharmaceutical companies avoid costly late-stage failures and brings safer medications to market faster. As the biopharmaceutical industry continues to invest heavily in developing novel therapies for cardiovascular diseases, demand for advanced preclinical cardiotoxicity screening solutions is expected to rise substantially.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀

Growing drug development activities: The increasing number of drugs in the clinical development pipeline is driving the need for advanced cardiotoxicity testing methods. Pharmaceutical companies are focusing on developing novel drugs to treat cardiovascular diseases, which requires thorough cardiotoxicity screening at the preclinical stage.

Stringent regulatory guidelines: Regulatory agencies have implemented stringent guidelines for drug safety evaluation. The FDA and EMA require comprehensive cardiac safety pharmacology studies before approval of new drug candidates. This is increasing the demand for reliable in-vitro cardiotoxicity screening assays.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀

High costs associated: Multiparametric cardiotoxicity assays using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are expensive due to the high costs involved in culturing and maintaining the cells. This poses a challenge for small pharmaceutical companies with limited budgets.

Lack of standardization: There is a lack of standardized protocols and guidelines for in-vitro cardiotoxicity testing. Different cell types and assay conditions are used across industry and academia, making it difficult to compare results. This challenges the reliability and reproducibility of cardiotoxicity screening.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85319

𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻

𝗧𝘆𝗽𝗲 𝗼𝗳 𝗔𝘀𝘀𝗮𝘆

Calcium Transient Assay

Cardiac Marker Detection

hERG Assay

Multi-ion Channel Assay

Others

𝗘𝗻𝗱-𝘂𝘀𝗲𝗿

Contract Research Organizations (CROs)

Pharmaceutical and Biotech Companies

Others

𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗣𝗿𝗼𝗳𝗶𝗹𝗲𝗱

Creative Bioarray

Agilent Technologies, Inc.

Hemogenix Inc.

Merck KGaA

Molecular Devices, LLC.

Miltenyi Biotec

FUJIFILM Cellular Dynamics

Enzo Life Sciences, Inc.

Axol Bioscience Ltd.

emka TECHNOLOGIES

Eurofins Discovery

Stemina Biomarker Discovery, Inc.

Evotec

𝗛𝗮𝘃𝗲 𝗔𝗻𝘆 𝗤𝘂𝗲𝗿𝘆? 𝗔𝘀𝗸 𝗢𝘂𝗿 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85319

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝗥𝗲𝗽𝗼𝗿𝘁 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:

Overview of global Multiparametric In-vitro Cardiotoxicity Testing market

A detailed key player’s analysis across regions

Analyses of global market trends, with historical data, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2031.

Insights into regulatory and environmental developments

Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Multiparametric In-vitro Cardiotoxicity Testing market

Major Company profiles

𝗪𝗵𝘆 𝗽𝘂𝗿𝗰𝗵𝗮𝘀𝗲 𝘁𝗵𝗶𝘀 𝗿𝗲𝗽𝗼𝗿𝘁:

Essential evidential and historic data deriving the comparison of market scenario is offered.

Efficient analysis applied with the help of analytical tools ensuring precise data is provided for business experts.

Market dynamics and futuristic outlook offers the statistical growth rate along with market estimations.

Current market trends determining the constant change in customer behavior is provided.

A good balance of theoretical and statistical data encompassing the entire keyword market essentials.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡-

Cold Plasma Market

Increase in adoption of atmospheric cold plasma in various applications due to an array of distinguishing properties can be ascribed to leading cold plasma market share of the segment in the past few years.

Sensor-Based Smart Catheters Market

North America is anticipated to provide a significant share of sensor-based smart catheters market opportunities to regional and global manufacturers

Nikhil Sawlani
Transparency Market Research Inc.
+ +1 518-618-1030
email us here
Visit us on social media:
Twitter
LinkedIn
YouTube